1. Home
  2. RIGL vs JRI Comparison

RIGL vs JRI Comparison

Compare RIGL & JRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • JRI
  • Stock Information
  • Founded
  • RIGL 1996
  • JRI 2012
  • Country
  • RIGL United States
  • JRI United States
  • Employees
  • RIGL N/A
  • JRI N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • JRI Finance Companies
  • Sector
  • RIGL Health Care
  • JRI Finance
  • Exchange
  • RIGL Nasdaq
  • JRI Nasdaq
  • Market Cap
  • RIGL 335.5M
  • JRI 367.7M
  • IPO Year
  • RIGL 2000
  • JRI N/A
  • Fundamental
  • Price
  • RIGL $41.50
  • JRI $13.44
  • Analyst Decision
  • RIGL Buy
  • JRI
  • Analyst Count
  • RIGL 5
  • JRI 0
  • Target Price
  • RIGL $38.20
  • JRI N/A
  • AVG Volume (30 Days)
  • RIGL 845.0K
  • JRI 68.0K
  • Earning Date
  • RIGL 08-05-2025
  • JRI 01-01-0001
  • Dividend Yield
  • RIGL N/A
  • JRI 9.38%
  • EPS Growth
  • RIGL N/A
  • JRI N/A
  • EPS
  • RIGL 5.43
  • JRI N/A
  • Revenue
  • RIGL $267,921,000.00
  • JRI N/A
  • Revenue This Year
  • RIGL $14.41
  • JRI N/A
  • Revenue Next Year
  • RIGL $15.97
  • JRI N/A
  • P/E Ratio
  • RIGL $7.64
  • JRI N/A
  • Revenue Growth
  • RIGL 105.62
  • JRI N/A
  • 52 Week Low
  • RIGL $12.00
  • JRI $9.70
  • 52 Week High
  • RIGL $43.72
  • JRI $12.12
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 86.20
  • JRI 60.54
  • Support Level
  • RIGL $38.43
  • JRI $13.27
  • Resistance Level
  • RIGL $41.25
  • JRI $13.46
  • Average True Range (ATR)
  • RIGL 2.50
  • JRI 0.08
  • MACD
  • RIGL 0.89
  • JRI 0.00
  • Stochastic Oscillator
  • RIGL 89.85
  • JRI 89.29

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About JRI Nuveen Real Asset Income and Growth Fund of Beneficial Interest

Nuveen Real Asset Income and Growth Fund is the United States-based closed-end fund. Its objective is to provide a high level of current income and long-term capital appreciation. The fund invests a majority of its managed assets in equity and debt securities issued by real asset related companies located anywhere in the world. Its plan involves investments in five security types, infrastructure common stock, REIT preferred stock and debt securities. Real asset-related companies include those engaged in owning, operating, or developing infrastructure projects, facilities, and services, as well as REITs.

Share on Social Networks: